Delhi court orders generic drugmaker to stop selling, producing antibiotic | Schizophrenia drug successful in Phase III trials | MSF wants drugmakers to slash vaccine prices

January 22, 2015
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory science

Top Story
Delhi court orders generic drugmaker to stop selling, producing antibiotic
Indian generic drug firm Glenmark Pharmaceuticals was ordered by the High Court of Delhi to stop the sales and manufacturing of the synthetic antibiotic Linezolid. The ruling is in response to a 2013 lawsuit by Symed Laboratories in which it claimed Glenmark used Symed's patented process to manufacture its drugs. Wall Street Journal (India) (1/20)
Share: LinkedInTwitterFacebookGoogle+Email
Get Creative: 10 Ways to Think Outside the Box
No matter your business, smart solutions come from out-of-the-box thinking. We all know creativity is king, but are you doing all you can to inspire and encourage creativity in your staff? Read the article and learn 10 ways to inspire creativity at your office.

EuropeSponsored By
Schizophrenia drug successful in Phase III trials
A Phase III trial of 101 patients by Gedeon Richter and Actavis found that cariprazine was associated with a 55% reduction in relapse risk in patients with schizophrenia when compared with a placebo. PharmaTimes (U.K.) (1/21)
Share: LinkedInTwitterFacebookGoogle+Email
MSF wants drugmakers to slash vaccine prices
Medecins Sans Frontieres criticized GlaxoSmithKline and Pfizer for the "skyrocketing" prices of their vaccines, including those for pneumococcal disease, which kills about 1 million children annually. MSF urged the firms to cut the prices of their vaccines to $5 per child to allow poor countries to afford them. The drugmakers defended their prices, saying they invested significant amounts of money and resources to develop the vaccines. Reuters (1/20)
Share: LinkedInTwitterFacebookGoogle+Email
How to Achieve IT Agility: A Survival Guide for IT Decision Makers
When business teams add new apps and services to already-strained networks, IT departments are accountable for making everything work. Is your team ready for this challenge? Read this eGuide to learn how IT teams are automating their networks, why they're utilizing Ethernet fabrics and SDN, and what success looks like as they regain network control and business relevance.

Asia Pacific
Genetic study identifies mutations associated with malaria drug resistance
Researchers analyzed 1,612 samples of the malaria parasite from Asia and Africa and found that mutations of kelch13 and four other genes were linked with resistance to artemisinin. Monitoring populations of the malaria parasite for the mutations could be used to track drug resistance, according to the study in the journal Nature Genetics. "Artemisinin is the best drug we have had for a very long time, and we want to continue this success story," said lead author Olivo Miotto from the Mahidol-Oxford Tropical Research Unit in Thailand. BBC (1/19)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
North America
Obama announces initiative to expedite development of personalized cures
President Barack Obama will ask Congress for funds to launch a "precision medicine initiative" to accelerate the development of personalized treatments against diseases such as cancer and diabetes and give all Americans access to personalized information needed to improve their health. "I want the country that eliminated polio and mapped the human genome to lead a new era of medicineā€Š -- one that delivers the right treatment at the right time," the president said Tuesday during his State of the Union address. Obama is expected to share details of the initiative in his fiscal 2016 budget, which will be released next month. Bloomberg Businessweek (1/20)
Share: LinkedInTwitterFacebookGoogle+Email
Stakeholders debate informed consent guidance
Proposed changes to informed consent guidelines could discourage research and clinical trial participation, some stakeholders say. The HHS proposal includes requiring potential clinical trial participants to be informed of all risks, including any effects being measured or tracked within the study, even if those effects were possible during a regular course of treatment. A conservative interpretation of the guidelines could have a chilling effect on research, some stakeholders said, but Office of Human Research Protections director Jerry Menikoff said only a clear, thorough explanation of potential dangers would be required. Kaiser Health News (1/20)
Share: LinkedInTwitterFacebookGoogle+Email
Genetic changes in Ebola virus may stall drug development
A study in the journal mBio has found 10 out of 600 Ebola gene mutations that could block the mechanisms of genetic sequence-based treatments such as monoclonal antibodies, small-interfering RNA and phosphorodiamidate morpholino oligomer drugs. The study suggests that genetic changes in the virus must be considered when developing possible Ebola therapies to make sure the treatments will not be rendered ineffective by those mutations. Business Standard (India)/Indo-Asian News Service (1/21), Yahoo/Agence France-Presse (1/20)
Share: LinkedInTwitterFacebookGoogle+Email
Report cites 5% growth for global ultrasound market
A Kalorama Information report says the global market for ultrasound devices is growing at a rate of 5% after posting revenue of $5.8 billion in 2014. The market research firm said the growth can be attributed to the ongoing trend toward handheld and portable systems. (free registration) (1/20)
Share: LinkedInTwitterFacebookGoogle+Email
Gilead licenses HIV drug to Strides Arcolab in 112 countries
Strides Arcolab secured non-exclusive rights to manufacture and distribute Gilead Sciences' HIV drug Tenofovir Alafenamide in 112 countries. The licensing deal includes a technology transfer to allow Strides to manufacture cheaper versions of the drug for developing countries. Business Standard (India) (1/20)
Share: LinkedInTwitterFacebookGoogle+Email
Featured Press Releases
DIA News
Help us recognize and award good work!
Each year, DIA recognizes our outstanding volunteers, globally and regionally, for their leadership, level of excellence and commitment to service. DIA has just launched a new INSPIRE Premier Awards for the Americas program that will shine the spotlight on our outstanding member volunteers in Canada, the U.S., Latin America and throughout the Americas region. Selections for these awards are through self-nomination or by peers -- please submit your nominations by Jan. 30!
Share: LinkedInTwitterFacebookGoogle+Email
Some people drink from the fountain of knowledge. Others just gargle."
-- Robert Anthony,
American business professor
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about DIA ->About DIA | Meetings & Trainings | News & Publications | Membership
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Lisa Gough
Advertising:  Meryl Harold
  P: 202.407.7828

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information